Feb. 8, 2024

The Centers for Medicare and Medicaid Services (CMS) Measures Management System posted a public comment period, open through Feb. 26, for four new breast cancer-related measures developed by Acumen, LLC. These include three quality measures and one episode-based cost measure intended to assess clinician performance in breast cancer screening and diagnosis and improve patient outcomes. An informational webinar about the measures will be held Feb. 13, 3–4pm ET.

The codes are:

  • Breast Cancer Screening Recall Rate Quality Measure (Outcome).
  • Breast Cancer Screening with an Eventual Breast Cancer Diagnosis: Positive Predictive Value 1 (PPV1) Quality Measure (Outcome).
  • Use of Biopsy After Diagnostic Follow-up with an Eventual Breast Cancer Diagnosis: Positive Predictive Value 3 (PPV3) Quality Measure (Outcome).
  • Breast Cancer Screening Episode-Based Cost Measure.

The testing process is an important step in determining whether these measures could eventually be adopted into CMS’ Merit-based Incentive Payment System. Feedback can be provided via the 2024 Beta Testing Feedback Survey through 11:59pm ET, Feb. 26.

If you have questions, contact Samantha Shugarman, American College of Radiology® Director of Quality Programs.


Related ACR News

  • CMS Announces Automatic MIPS Exemption for Providers Affected by Natural Disasters

    CMS announced it will allow automatic exemption from the 2025 MIPS for providers in certain Texas and California counties affected by natural disasters.

    Read more
  • ACR Congratulates Sirtex

    The ACR Center for Research and Innovation served as the imaging contract research organization for the DOORwaY90 clinical trial.

    Read more
  • Dangerous Scope of Practice Bills Fail in States

    ACR advocates for proper supervision and interpretation of imaging exams by trained radiologists to ensure quality care.

    Read more